...
首页> 外文期刊>American Journal of Epidemiology >Risk of Second Primary Malignancies in Women with Papillary Thyroid Cancer
【24h】

Risk of Second Primary Malignancies in Women with Papillary Thyroid Cancer

机译:乳头状甲状腺癌女性继发原发性恶性肿瘤的风险

获取原文
获取原文并翻译 | 示例

摘要

Second malignancies in women diagnosed with thyroid cancer are of concern given the young average age at diagnosis and excellent survival. Data from the California Cancer Registry were used to evaluate the risk of second primary cancers among a retrospective population-based cohort of 10,932 women diagnosed with papillary thyroid cancer between 1988 and 1999. Follow-up was calculated from 2 months until the diagnosis of a second primary cancer, death, loss to follow-up, or December 31, 1999, whichever occurred first. Standardized incidence ratios, based on age-specific cancer incidence rates for California women, were calculated. During a total of 50,938 person-years of follow-up (mean: 4.7 years), 279 women developed a second primary cancer. The incidence of invasive breast cancer was not elevated compared with California women overall (standardized incidence ratio (SIR) = 0.9, 95% confidence interval (CI): 0.7, 1.1) or when stratified by age, race/ethnicity, follow-up, or radiation treatment. An excess of in situ breast cancer (SIR = 1.6, 95% CI: 1.0, 2.4), kidney cancer (SIR = 3.9, 95% CI: 2.2, 6.3), and melanoma (SIR = 2.1, 95% CI: 1.3, 3.2) limited to the first 5 years after diagnosis was observed. Women with papillary thyroid cancer are at increased risk of in situ, but not invasive, breast cancer, kidney cancer, and melanoma.
机译:考虑到诊断时的平均年龄年轻和存活率高,被诊断为甲状腺癌的女性的第二恶性肿瘤值得关注。加利福尼亚癌症登记处的数据用于评估1988年至1999年之间以回顾性人群为基础的10932名被诊断患有甲状腺乳头状癌的女性中第二原发癌的风险。随访时间为2个月,直到第二次被确诊。原发性癌症,死亡,无法随访或1999年12月31日,以较早发生者为准。根据加利福尼亚女性的特定年龄癌症发病率,计算标准化发病率。在总共50938人年的随访中(平均4.7年),有279名妇女患了第二原发癌。与加利福尼亚州女性总体(标准发病率(SIR)= 0.9,95%置信区间(CI):0.7、1.1)或按年龄,种族/民族,随访,或放射治疗。原位乳腺癌(SIR = 1.6,95%CI:1.0,2.4),肾癌(SIR = 3.9,95%CI:2.2,6.3)和黑色素瘤(SIR = 2.1,95%CI:1.3, 3.2)仅限于观察到诊断后的最初5年。患有甲状腺乳头状癌的妇女原位(但不是浸润性)乳腺癌,肾癌和黑色素瘤的风险增加。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号